Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 05, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: March 01, 2007
- Previous Holdings: 16,282,040 ADRs
- New Holdings: 16,237,928 ADRs
- Average Price: $56.92
- Reason: Movement in the fund.
Two directors, Dr J P Garnier and Dr M M Slaoui, are noted as potentially interested in the shares held in this discretionary fund, similar to other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the impact of the 44,112 ADR reduction in the US Retirement Savings Plan on overall insider ownership percentages.
- Confirm the specific roles of Dr J P Garnier and Dr M M Slaoui regarding their potential interest in the fund.
- Note that this filing does not contain operational or financial performance data for the period.